Bristol-Myers up 4% after beating Q1 estimates and raising FY17 EPS guidance, helped better than expected sales of cancer drug Opdivo (53.77)
Opdivo sales grew 60% to $1.13 bln; estimates were closer to $1 bln. Merck (MRK) was thought to be taking market share with its rival immunotherapy checkpoint inhibitor Keytruda